IMAGING AND ADVANCED GUIDANCE FOR WORKFLOW OPTIMIZATION IN INTERVENTIONAL ONCOLOGY

Informations projet

IMAGIO

N° de convention de subvention: 101112053

DOI

10.3030/101112053

Date de signature de la CE 15 Mai 2023

Date de début 1 Mai 2023

Date de fin 30 Avril 2027

Financé au titre de

• Health

Coût total

€ 37 263 739,26

Contribution de l’UE

€ 24 307 086,87

Coordonné par

PHILIPS MEDICAL SYSTEMS NEDERLAND BV
Netherlands

Periodic Reporting for period 2 - IMAGIO (IMAGING AND ADVANCED GUIDANCE FOR WORKFLOW OPTIMIZATION IN INTERVENTIONAL ONCOLOGY)

Période du rapport: 2024-05-01 au 2025-04-30

Résumé du contexte et des objectifs généraux du projet

Cancer accounts for nearly 10 million deaths in 2020, or nearly one in six deaths. Lung and liver cancers were among the top three leading causes of cancer death in 2020 with 1.8 million and 830.000 deaths, respectively. On the other hand, soft tissue sarcomas are a relatively uncommon cancer diagnosed in about 1% of all adults but much more common in children and young adults, accounting for 7–10% of paediatric malignancies; they are an important cause of death in the 14–29 years age group.
Interventional Oncology involves miniaturised instruments (biopsy needles, ablation electrodes, intravascular catheters) and minimally-invasive access, guided by imaging techniques (X-ray, ultrasound, computed tomography, magnetic resonance imaging) – to target cancer with ablative or localised drug delivery strategies. Through minimally-invasive access, Interventional Oncology lowers the risk for complications; its precision targeting can provide an outcome in directing treatment with a high therapeutic dose – when otherwise not feasible. Advanced intra- and pre-procedural imaging-based techniques have only recently been introduced to the clinical practice, requiring maturation and full integration in standard care pathways.
IMAGIO will leverage Interventional Oncology in the clinical setting to improve cancer survival outcomes through minimally invasive, efficient, and affordable care pathways for three cancer types: liver, lung, and sarcoma. The barriers to clinical adoption will be removed through pioneering clinical studies that will generate the early evidence required for massive clinical roll-out.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Objective 1. Multimodal imaging for fast radioembolisation therapy of liver cancer (addressed by WP1, WP2, WP6): The software that will support the application of the current hybrid C-arm prototype (for the IXSI-2 study) is nearing completion. During the next reporting period, the software will undergo intensive testing. The first steps were taken to solve the limitations of the combined X-ray imager/gamma camera used in the current hybrid C-arm prototype. A detailed simulation model of the hybrid C-arm was performed and tested with the standard scintillator, as well as a long list of low-afterglow scintillation materials that could potentially be used instead of the standard scintillator – leading to a shortlist of the most promising material candidates. A clinical study has been prepared to generate evidence on the potential of angiotensin injection to further improve the efficiency of radioembolisation.
Objective 2. Multimodal thermal ablation therapy for liver cancer (addressed by WP1, WP3, WP6): A systematic literature review was performed to develop computational models supporting optimal treatment decisions and prediction of re-occurrence. A large European observational cohort study (A-IMAGIO) with retro- and prospective data has been set up and undergoing approval at several clinical sites. Research has been performed on tools to predict the ablation zone accurately. The effectiveness of the BioXmark markers in determining the actual tissue shrinkage was tested. LUMC developed a method based on deep learning segmentation algorithms to automatically evaluate the ablation treatment success, trained with existing data. For the same purpose, UM investigated using a multimodality method combining pre-ablation MRI of the tumour and post-ablation CT (post-operatively ablated volumes).
Objective 3. Multimodal diagnosis and therapy for early-stage lung cancer (addressed by WP1, WP4): A first design has been made to support eliciting the values individuals attach to different diagnostic and therapeutic strategies and the corresponding expected health outcomes. PMS developed novel imaging protocols and intra-operative guidance to improve the imaging capabilities of the CBCT-guided navigation bronchoscopy procedure. JPNV delivered prototype steerable catheters, further successfully evaluated and validated for usability and accuracy with the Radboud in two cadaver labs. A study initiation package was prepared for its clinical validation (ACTIFLEX). Progress has been made towards developing instant, detailed, and 3D histologic analysis of pathology through higher harmonic generation (HHG) microscopy and artificial intelligence (AI). Data collection to validate HHG images against HE images started in VU and Radboud (VALIDIAG study, >100 biopsy specimens). An AI algorithm for malignancy detection was developed using an existing dataset from the VU. A novel multiplex immunohistochemistry (IHC) staining methodology is being developed by ETHZ, to enable further analysis of the tumour microenvironment for novel biomarkers. Immuno-PET imaging will be developed to evaluate the patients' response to immune therapies. A delay in the regulatory strategy regarding the IO treatment arm initially planned for the study caused a re-evaluation of possible treatment substrates. Slight timeline adjustments were brought to the initial plan (GA amendment).
Objective 4. Multimodal MR-HIFU-enabled therapy for sarcoma (addressed by WP1, WP5, WP6): A prototype for a versatile and flexible MR-HIFU platform was developed and built and initial tests for the delivery of ablation have been performed. A tool for automated segmentation of the subcutaneous fat from MR images has been developed and tested. Motion fields from MR acquisitions that feed into motion correction strategies were assessed. In addition, research into improved 4D sampling strategies was started to support more accurate treatment planning. Initial preclinical experiments in phantoms and ex-vivo tissue have been performed, and in-vivo animal experiments have been prepared. The clinical study is in preparation.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Objective 1: A real-time interventional dosimetry based on hybrid imaging and real-time interventional dosimetry based on hybrid imaging during the intervention. The conventional radioembolisation workflow will be expedited by applying an innovative hybrid C-arm (prototype available) that allows for microsphere imaging during the catheterisation, reducing the number of steps from three to one. New scintillation materials are being characterised to select the best performing one for a new, compact detector design, fully compatible with conventional C-arm.
Objective 2: To allow broader applicability in the hospital environment, a modality-agnostic solution will be developed instead of ultrasound-based real-time device tip navigation. A protocol has been developed for robotic needle navigation during liver ablation using MicromateTM, an accessible device for operators with varying levels of expertise. Novel approaches were also developed for ablation success evaluation.
Objective 3: Flexible catheters for navigation bronchoscopy are being evaluated. Instant pathological analysis in the OR through High Harmonic Generation microscopy will enable intra-procedural diagnostics. This method and navigation bronchoscopy will allow a one-stop shop where definitive diagnosis and treatment can be performed during the same procedure.
Objective 4: A prototype for a vendor-agnostic HIFU system is being developed. First-in-human clinical trials are being planned, with preclincial experiments having been organised.

IMAGIO overall concept (background)